- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Mixed connective tissue disease.
Displaying page 1 of 3.
EudraCT Number: 2012-003633-42 | Sponsor Protocol Number: RBHIPF004 | Start Date*: 2013-10-18 | |||||||||||||||||||||||||||||||
Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease | |||||||||||||||||||||||||||||||||
Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004937-19 | Sponsor Protocol Number: CMHV370A12201 | Start Date*: 2021-09-08 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with ... | ||||||||||||||||||
Medical condition: Sjögren’s syndrome Mixed connective tissue disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001108-11 | Sponsor Protocol Number: EORTC protocol 62033 | Start Date*: 2004-11-08 | |||||||||||
Sponsor Name:European Organisation for the Research and Treatment of Cancer | |||||||||||||
Full Title: A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-bas... | |||||||||||||
Medical condition: Soft Tissue Sarcoma (STS) is a rare group of heterogeneous mesenchymal cancers originating from connective tissue. There are multiple histological subtypes of STS. At present all these subtypes are... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004272-20 | Sponsor Protocol Number: E7389-E044-207 | Start Date*: 2006-10-23 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27) | |||||||||||||
Medical condition: Advanced and/or metastatic soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003239-38 | Sponsor Protocol Number: PH-L19TNFDOX2-03/16 | Start Date*: 2017-07-28 | ||||||||||||||||
Sponsor Name:Philogen S.p.A. | ||||||||||||||||||
Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien... | ||||||||||||||||||
Medical condition: Unresectable or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001861-40 | Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061) | Start Date*: 2006-09-21 | |||||||||||
Sponsor Name:SYSTEMS MEDICINE, LLC | |||||||||||||
Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma | |||||||||||||
Medical condition: Advanced or metastatic soft tissue sarcoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017261-32 | Sponsor Protocol Number: KKSH077 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | |||||||||||||
Full Title: Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma | |||||||||||||
Medical condition: Relapsed or metastatic soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005294-60 | Sponsor Protocol Number: CRAD001C24114 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | |||||||||||||
Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004856-57 | Sponsor Protocol Number: IPM2002 | Start Date*: 2008-12-31 | |||||||||||
Sponsor Name:ZIOPHARM ONCOLOGY, INC | |||||||||||||
Full Title: A Phase II multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO) | |||||||||||||
Medical condition: Unresectable or metastatic soft-tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001284-44 | Sponsor Protocol Number: MEDLARV-CLIN-01 | Start Date*: 2011-11-14 |
Sponsor Name:MAGGOT 2006 Egészségügyi, Kereskedelmi és Szolgáltató Ltd. | ||
Full Title: A RANDOMIZED, OPEN, SELF-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF LARVAL THERAPY IN PATIENTS WITH LEG ULCERS | ||
Medical condition: Venous or mixed venous/arterial ulcers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004750-15 | Sponsor Protocol Number: AIO-STS-0415 | Start Date*: 2017-10-06 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. | ||||||||||||||||||
Medical condition: advanced or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003011-12 | Sponsor Protocol Number: RR08/8613 | Start Date*: 2009-03-30 |
Sponsor Name:University of Leeds | ||
Full Title: Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001581-10 | Sponsor Protocol Number: TCP-101 | Start Date*: 2014-07-22 |
Sponsor Name:Tigercat Pharma, Inc. | ||
Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritus | ||
Medical condition: Chronic pruritus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002131-34 | Sponsor Protocol Number: GS-US-357-1394 | Start Date*: 2015-05-07 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004168-30 | Sponsor Protocol Number: STS001 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma | |||||||||||||
Medical condition: Metastatic or advanced soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006192-13 | Sponsor Protocol Number: C200-006 | Start Date*: 2006-06-22 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals US, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SI... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) is a condition that is characterized by increased pulmonary arterial pressure and vascular resistance that can lead to right ventricular failure and death. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PT (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005270-10 | Sponsor Protocol Number: NALISO-II-20-1 | Start Date*: 2021-08-18 | |||||||||||
Sponsor Name:LABORATOIRES SMB S.A | |||||||||||||
Full Title: A randomized, partially blinded, parallel study to evaluate the effects of nacystelyn in combination with isotretinoin in the treatment of recalcitrant acne vulgaris. | |||||||||||||
Medical condition: Recalcitrant acne vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005887-14 | Sponsor Protocol Number: B1321003 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS ... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021344-17 | Sponsor Protocol Number: CQTI571A2102 | Start Date*: 2011-01-28 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-admini... | |||||||||||||
Medical condition: Pulmonary arterial hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002243-42 | Sponsor Protocol Number: GCT1021-01 | Start Date*: 2016-10-25 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
